Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A

Chang Han Chen, Hsin Ting Tsai, Hui Ching Chuang, Li Yen Shiu, Li Jen Su, Tai Jan Chiu, Sheng Dean Luo, Fu Min Fang, Chao Cheng Huang, Chih Yen Chien

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Conventional therapeutic processes in patient with OSCC are associated with several unfavorable effects leading to patients with poor survival rate. Metformin has been shown to protect against a variety of specific diseases, including cancer. However, the precise roles and mechanisms underlying the therapeutic effects of metformin on OSCC remain elusive. In the current study, in vitro and xenograft model experiments revealed that metformin inhibited growth and metastasis of oral cancer cells. Importantly, metformin-restrained tumorigenesis of oral cancer was accompanied with strong decrease of both Aurora-A and Late SV40 Factor (LSF) expressions. Furthermore, LSF contributed to Aurora-A-elicited malignancy behaviors of oral cancer via binding to the promoter region of Aurora-A. A significant correlation was observed between LSF and Aurora-A levels in a cohort of specimens of oral cancer. These findings showed that a novel LSF/Aurora-A-signaling inhibition supports the rationale of using metformin as potential OSCC therapeutics.

Original languageEnglish
Article number1358
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - 1 Dec 2017

Fingerprint

Dive into the research topics of 'Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A'. Together they form a unique fingerprint.

Cite this